ReviewInflammopharmacology2025
The promise of stem cell therapies for cellular recovery after stroke.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological conditions are the consequence of impairment in the neuronal and glial cells. These neuronal disorders remain a significant concern for nations with industrialized economies. Even though our comprehension of the pathophysiology of strokes has grown over the past several years, greater understanding and additional education remain crucial for advancement in the field of stroke recovery. Present treatments are not optimal for each individual and cannot substantially improve the state of the disease. In the interim, the majority of the recipients still have neurological abnormalities even after receiving efficient thrombolysis; therefore, as soon as stroke damage takes place, recuperative therapies that foster brain reconfiguration and recognition are essential. Present treatments are not optimal for each individual and cannot substantially improve the state of the disease. Since the initial clinical trials were conducted more than 15 years ago, adult stem cells have been used for stem cell treatment in stroke patients. Although stem cells have shown potential in exploratory research and early therapeutic pilot studies, the use of cellular therapy to treat ischemic stroke is still in its infancy. Among the factors considered for cellular therapy for ischemic stroke are the types of stem cells, the mechanism of stem cell therapy, when and how to infuse stem cells, and the therapeutic applications of stem cell-based therapy for treating stroke.
Indexed as
Identifiers
41205132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.